GSK, GlycoVaxyn collaborate on bacterial vaccine development

12/20/2012 | Genetic Engineering & Biotechnology News

GlaxoSmithKline Biologicals and GlycoVaxyn agreed to use the latter's bioconjugation technology to develop novel bacterial vaccines. The deal, which covers a set of pathogen targets, gives GSK an exclusive licensing option. GSK will give GlycoVaxyn an upfront payment and equity investment plus milestone fees and royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY